RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

What a brutal six months it’s been for Illumina. The stock has dropped 30.9% and now trades at $84.65, rattling many shareholders. This may have investors wondering how to approach the situation.

Illumina stock skidded Tuesday after China signaled it would ban the company from importing its gene-mapping products.

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

The stock's fall snapped a two-day winning streak.

Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its ...

This workforce reduction comes at a time when Illumina is contending with geopolitics influencing its market, increased ...